Fudan University moves a four-drug first-line strategy into metastatic gastric cancer
A new phase 2 study from Fudan University is set to test an aggressive first-line treatment strategy for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed and has spread. The regimen combines retlirafusp alfa, zeprumetostat, apatinib, and standard CAPOX chemotherapy, reflecting a deliberate attempt to hit the disease from several biologic angles at once: cytotoxic tumor kill, anti-angiogenic pressure, and pathway-level modulation layered on top of chemotherapy.
The study is exploratory, but its design is clinically ambitious. Investigators plan to enroll an estimated 55 participants, with analysis also incorporating the 6 patients treated during dose escalation. The population is tightly defined: adults 18 to 65 years old, ECOG performance status 0 to 1, no prior anticancer therapy for unresectable locally advanced or metastatic disease, and at least one measurable lesion by RECIST 1.1. Tumor assessments will occur every two treatment cycles, which should provide a relatively early read on whether the combination is producing measurable shrinkage or disease stabilization.
One sentence captures the logic of the trial: this is a biomarker-agnostic but biologically layered assault on metastatic gastric cancer in a setting where early treatment choice often shapes the rest of the patient’s course.
Why the regimen is built around multiple mechanisms
The backbone of the study is familiar. CAPOX pairs capecitabine with oxaliplatin, a standard chemotherapy platform in gastric cancer that remains a common first-line choice because it can produce rapid tumor debulking in symptomatic, high-burden disease. The newer elements are what make this protocol worth watching. Retlirafusp alfa and zeprumetostat are being added to apatinib, a drug that targets tumor angiogenesis through VEGF pathway inhibition, creating a regimen that aims to starve the tumor vasculature while attacking proliferative signaling and DNA-damaging vulnerability at the same time.
That kind of strategy makes biological sense in metastatic gastric and gastroesophageal junction disease, where vascular supply, growth signaling, and chemotherapy resistance often reinforce one another. Anti-angiogenic therapy can alter tumor perfusion and the microenvironment, while additional targeted modulation may deepen tumor control beyond what chemotherapy alone can achieve. In a disease that frequently presents late and progresses quickly, the appeal of a combination approach is clear: if a tumor is going to escape, it may do so through more than one pathway, and a single agent may not be enough to keep pace.
Eligibility criteria reveal the safety concerns built into the protocol
The inclusion and exclusion criteria show how much caution surrounds this regimen. Participants must have adequate bone marrow reserve, liver and kidney function, acceptable coagulation parameters, and no active bleeding. They also need no evidence of uncontrolled hypertension, recent major cardiovascular disease, or significant thromboembolic history. Those limits are not cosmetic. Apatinib, as a VEGF-directed agent, can aggravate hypertension and bleeding risk, so the study excludes patients who already carry those vulnerabilities into treatment.
The protocol also excludes people with HER2-positive disease, active autoimmune disorders, uncontrolled infections, recent transplants, or conditions that could interfere with oral drug absorption. Prior malignancy, major cardiac instability, and significant hepatic viral activity are also disqualifying. This is a population selected not just for disease status but for physiological resilience, a reminder that multi-agent regimens in upper gastrointestinal oncology often demand a narrow therapeutic window.
A single line in the criteria speaks volumes: patients with active bleeding or a high-risk primary gastric lesion are not eligible.
The trial’s clinical value lies in response signals, not only survival endpoints
Because this is an exploratory phase 2 study, the immediate question is not whether the regimen can redefine the standard of care overnight. The more practical question is whether the combination can generate a response pattern strong enough to justify deeper development. For unresectable locally advanced or metastatic gastric cancer, early tumor response matters because it can reduce symptoms, protect organ function, and create options later in the disease course. A regimen that controls disease early may also improve tolerance of subsequent therapy by limiting clinical decline.
The study’s design suggests that investigators want a fast and interpretable signal. Measuring tumors every two cycles should reveal whether the quadruplet has enough activity to warrant larger testing. The use of the recommended phase 2 dose from the escalation phase also indicates that the development plan has already entered a dose-finding phase, even if the current record does not provide escalation outcomes. What remains unknown is how much additional toxicity the four-drug combination will impose compared with the expected burden of CAPOX alone plus targeted therapy. In gastric cancer, efficacy and tolerability are often inseparable; a potent regimen that cannot be delivered consistently has limited clinical value.
What this study may add to first-line gastric cancer care
The target population here has a particularly difficult diagnosis: HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma with no prior systemic therapy for advanced disease. That setting has long depended on chemotherapy backbones, with targeted additions typically reserved for select biologic subsets or specific clinical circumstances. This protocol instead asks whether a broader combinatorial approach can improve first-line control in an unselected HER2-negative group.
Its estimated start date is October 2026, with primary completion and full completion both projected for December 2028. No location data are listed yet, and the study is still marked not yet recruiting. Even at this early stage, the trial reflects a familiar and pressing oncology problem: how to intensify treatment without pushing patients beyond what they can safely tolerate. The answer will depend on response depth, durability, and the adverse-event profile that emerges once treatment begins.
The current record leaves one central uncertainty unresolved: whether adding retlirafusp alfa and zeprumetostat to apatinib and CAPOX will improve disease control enough to justify the added complexity of treatment in a population already constrained by bleeding risk, cardiovascular risk, and the physiologic toll of advanced gastric cancer.